An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
2020-07-04
عنوان الدراسة
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
داعم الدراسة
AbbVie
دواء الدراسة
ABT-450/r/ABT-267 ABT-333Ribavirin (RBV)
رقم بروتوكول الدراسة
M14-423
حالة الدراسة
Ongoing
موقع الدراسة
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
مرحلة الدراسة
3b
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。